-Toshihito Seki Researcher Activity Profile

Research Author Detailed Information 

Toshihito Seki Publication Rate By Year

Toshihito Seki has published 1 paper(s) in 2006, 6 paper(s) in 2007, for a total of 7 research publications in total.

Toshihito T Seki Author Information

LAST NAME: seki

FIRST NAME: toshihito

INITIALS: T

AFFILIATION:

Papers

Toshihito Seki's Publication Record

1. A proposal of the modified liver damage classification for hepatocellular carcinoma. Year Published: 2006
Departments of Gastroenterology and Hepatology, Kinki University School of Medicine, 377-2, Ohno-Higashi, Osaka-Sayama 589-8511, Japan.
2. Clinicopathologic study of small hepatocellular carcinoma with microscopic satellite nodules to determine the extent of tumor ablation by local therapy. Year Published: 2007
Department of Gastroenterology and Hepatology, Kansai Medical University, Moriguchi, Osaka, Japan. ikedakoz@takii.kmu.ac.jp
3. The combination of glycyrrhizin and lamivudine can reverse the cisplatin resistance in hepatocellular carcinoma cells through inhibition of multidrug resistance-associated proteins. Year Published: 2007
Third Department of Internal Medicine, Division of Gastroenterology and Hepatology, Kansai Medical University, Hirakata 573-1191, Japan.
4. The combination of glycyrrhizin and lamivudine can reverse the cisplatin resistance in hepatocellular carcinoma cells through inhibition of multidrug resistance-associated proteins. Year Published: 2007
Third Department of Internal Medicine, Division of Gastroenterology and Hepatology, Kansai Medical University, Hirakata, Japan.
5. Severe complications of radiofrequency ablation therapy for hepatocellular carcinoma: an analysis of 3,891 ablations in 2,614 patients. Year Published: 2007
Department of Gastrointestinal Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan. kasugai-hi@mc.pref.osaka.jp
6. Severe complications of radiofrequency ablation therapy for hepatocellular carcinoma: an analysis of 3,891 ablations in 2,614 patients. Year Published: 2007
Department of Gastrointestinal Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan. kasugai-hi@mc.pref.osaka.jp
7. The combination of glycyrrhizin and lamivudine can reverse the cisplatin resistance in hepatocellular carcinoma cells through inhibition of multidrug resistance-associated proteins. Year Published: 2007
Third Department of Internal Medicine, Division of Gastroenterology and Hepatology, Kansai Medical University, Hirakata, Japan.